When does weight loss start on Wegovy — and how long does it take to notice?

The decision you're really facing: patience vs. realistic expectations

When you start Wegovy, the first question is rarely "will it work?", it's "when will I actually see it working?" That's a fair thing to want answered before committing. The honest answer is that the timeline splits into two distinct phases, and conflating them leads to unnecessary alarm in the early weeks or premature optimism about what the first month will deliver.

Phase one covers roughly the first eight to sixteen weeks. Your dose is low, 0.25mg is the starting point, a level chosen specifically to let your digestive system settle rather than to produce maximum appetite suppression. During this phase some people notice a modest drop on the scales, others notice very little. Both are normal. The absence of dramatic early results is not a sign that semaglutide isn't working; it's a sign the schedule is doing its job.

Phase two begins as your prescriber moves the dose upward. Appetite typically falls more noticeably from around the 1.0mg and 1.7mg steps, and for most people the clearest progress comes after reaching or approaching the 2.4mg maintenance level. That can be anywhere from four to six months into treatment, depending on how your body responds and how smoothly you move through the steps.

Our detailed guide to when Wegovy starts working breaks this timeline down further, including what counts as a response by clinical measures. The key point here is that the decision to stay patient through an apparently quiet early phase is almost always the right one, provided you're in regular contact with your prescriber.

What the trial data tells us about when weight loss appears

The STEP 1 trial (published in the New England Journal of Medicine and involving 1,961 adults with obesity or overweight and at least one weight-related condition) followed participants for 68 weeks at the 2.4mg dose. Average weight loss across that period was approximately 15% of starting body weight. That figure is often quoted as a headline without the timeline attached, which matters: most of that loss accumulated gradually, with the steeper reductions occurring during the middle and later months of the trial as participants were established on maintenance dosing.

Published data from earlier weeks consistently shows smaller losses, typically 1–3% by week four to eight at the lower titration doses. Framing that against the 68-week average is useful: it means that what you see in month one is roughly one-fifth or less of what the full treatment course can produce. If you want a clearer sense of when you can expect to start losing weight on Wegovy, that depends heavily on which dose step you're currently on and how your body is responding to it.

The Wegovy treatment overview covers the full clinical background if you want the broader picture on how semaglutide compares across the dose steps. For now, the trial data points to one practical conclusion: consistent, steady loss over the full course outweighs any single week's reading.

What you can do to support early progress, and what to watch for

Semaglutide works by reducing appetite and slowing gastric emptying, which means you naturally eat less. But how well that translates to the scales in the early weeks depends partly on what you do with that reduced appetite. Protein intake tends to suffer first when people eat less overall, and insufficient protein during active weight loss can mean the body draws on muscle rather than fat, a loss that may not show up as clearly in your energy levels or body composition.

The NHS's patient information on semaglutide sets out the common side effects, nausea and digestive discomfort are most frequent in the early weeks, especially around dose changes. They usually settle within days. If they don't, that's a conversation for your prescriber, not a reason to quietly stop the medicine.

One practical note: timing matters in small ways. People who start mid-month sometimes lose track of where they are in the titration schedule around a bank holiday or a holiday week. Keeping a simple note of your injection dates and the current dose step avoids confusion, and means that question is never left to memory when your next clinical review arrives. If you're still deciding when to start, building your start date around a predictable few weeks can help.

If you're curious about the cost side of treatment before beginning, our honest breakdown of Wegovy pricing in the UK explains what a legitimate private prescription includes and why headline prices don't always tell the full story.

When to flag slow progress with your prescriber

NICE's guidance on semaglutide (TA875) includes a clinical checkpoint: if weight loss is less than 5% after six months at the maintenance dose, continuing treatment should be reviewed. That benchmark is for the full maintenance period, not for week four, so a slow start is not automatically a clinical concern. What it does mean is that progress should be tracked over time, and that clinical re-review is built into legitimate treatment, not optional.

If you've been on Wegovy for several months and feel uncertain whether anything is changing, the right move is to raise it at your next review rather than increase your dose without guidance or compare your progress to someone else's. Weight loss with semaglutide varies meaningfully between people, starting weight, diet, activity level, gut motility and other factors all influence the pace.

Questions about how your own timeline is looking are exactly what prescribers at a regulated service are there for. Our page on when weight loss begins with Wegovy addresses some of the specific questions that come up most often during those early months. If you're not yet in treatment and want to understand whether Wegovy is clinically appropriate for you, checking your eligibility with our prescribers is the natural first step.